account_id none on file
legal_name Ernexa Therapeutics Inc.
ticker ERNA
cik 748592
domain eternatx.com
linkedin_company_url https://www.linkedin.com/company/ernexa-therapeutics/?viewAsMember=true
entry_point_account_id none on file
name Eterna Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Cambridge, MA, United States
sector index/company/sector/health-care/
calls 0 filings 8 executives 4 family 0
why_nownone on file
callsnone on file
filings
supply expenses, travel expenses, stock-based compensation, allocated occupancy costs, and depreciation. 2 Other includes expenses related to insurance, occupancy expense, information technology, travel, depreciation and other miscellaneous expenses.
filing / Aug 6, 2026 / receipt
planned capital purchases or reduce expenses may be insufficient to cover shortfalls in available funds. If we require additional capital,
filing / Aug 6, 2026 / receipt
Keeley as Fractional Chief Financial Officer Effective August 10, 2026, the Company engaged Mark J. Keeley as a fractional Chief Financial Officer on a consulting basis pursuant to a Consulting Agreement dated August 5, 2026 (the "Keeley Agreement"), and designated Mr.
filing / Aug 6, 2026 / receipt
the Company may undertake to reduce planned capital purchases or reduce expenses may be insufficient to cover shortfalls in available
filing / Aug 6, 2026 / receipt
lease termination agreement was accounted for as a modification to the Manhattan Office lease rather than as a lease termination because
filing / Aug 6, 2026 / receipt
the Company did not contemporaneously terminate the Manhattan Office lease upon the February 18, 2026 modification date and had a continued
filing / Aug 6, 2026 / receipt
and cost savings for companies. Under this procedure, only one copy of the Notice of Internet Availability, and if applicable, Notice
filing / May 11, 2026 / receipt
cost reduction measures; and/or (xxiii) strategic plan development and implementation. (c) At the discretion of the Committee, the settlement of Performance Share Units or Performance Shares may be in cash, Shares of equivalent value, or in some combination thereof, as set forth in the Award Agreement.
filing / May 11, 2026 / receipt
executives
| Dorothy J. Clarke | director | - | receipt |
| James Bristol | director | - | receipt |
| Jeff Berg | Chairman | - | receipt |
| Sanjeev Luther | Robert Pierce, MD | - | receipt |
familynone on file
upcoming
| 2026-11-06 | earnings call | scheduled | ir |
changes
| 2023-12-20 | President and Chief Executive Officer, appointed | sec_8k |
| 2023-11-01 | director, appointed | sec_8k |
| 2023-08-31 | director, appointed | sec_8k |
| 2023-08-10 | President and Chief Executive Officer, departed | sec_8k |
| 2023-01-04 | President and Chief Executive Officer, appointed | sec_8k |
| 2022-09-01 | Chief Scientific Officer, departed | sec_8k |
| 2012-06-05 | Chairman, appointed | sec_8k |
mcp_package_hint
slug eterna-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$